Abstract:The analysis of serum endogenous peptides holds promise for disease study and drug discovery, whereas it is relatively unexplored given its challenges in analysis reproducibility and reliability. Here, we developed a streamlined detection platform for high-sensitive and reproducible serum peptidome profiling by data-independent acquisition (DIA) strategy. Compared to the classic data-dependent acquisition (DDA), our developed DIA approach can quantify almost twice the number of peptides with half the median coefficients of variation detected for DDA. The platform enables reproducible profiling of thousands of peptides and their post-translational modifications after simple sample preparation. The developed platform was subsequently utilized in the serum peptidome study of clear-cell renal cell carcinoma (ccRCC). A total of 31 ccRCC patients and 31 healthy volunteers were enrolled. Significant differences in serum peptidome patterns were observed between the two groups, allowing us to distinguish ccRCC patients from healthy volunteers clearly. A total of 833 modified peptides were found significantly changed in the ccRCC patients. The study demonstrated the high potential of serum peptidome in cancer detection and the feasibility and advantage of applying the DIA-based platform on large-scale serum peptidomic analysis for biomarker discovery. SIGNIFICANCE: Serum peptidomic study proves to be challenging given its low abundance and instability of endogenous peptides. In this study, we developed a fast, reproducible and accurate detection platform by DIA-based MS method for streamlined serum peptidome profiling. The developed platform was then utilized in the serum peptidome study of ccRCC. To our knowledge, this is the first report to apply DIA strategy to disease related peptidomic studies. The large difference in serum peptidome profiles enabled us to distinguish ccRCC patients from healthy volunteers clearly, illuminating the great potential of serum peptidome in cancer diagnosis. The discovered significantly changed peptides provided a better understanding of the pathophysiological changes in ccRCC.

Multi-dimensional on-particle detection technology for multi-category disease classification

Diagnosis of pancreatic adenocarcinoma using protein chip technology.

Profiling of Endogenous Serum Phosphorylated Peptides by Titanium (IV) Immobilized Mesoporous Silica Particles Enrichment and MALDI-TOFMS Detection

Mining disease information in low molecular weight peptides based on nanoporous silicon micro-flake

Capture, Enrichment, and Mass Spectrometric Detection of Low-Molecular-Weight Biomarkers with Nanoporous Silicon Microparticles

Fast and Precise Quantification of Serum Biomarkers and Simultaneous Recognition of Multiple Diseases Enabled by a Stable Isotope-Labelled Peptides Assisted High-Throughput MRM Strategy

Palladium Modified Porous Silicon As Multifunctional Maldi Chip for Serum Peptide Detection

Diagnosis and Subtype Classification on Serum Peptide Fingerprints by Mesoporous Polydopamine with Built-in Metal-Organic Framework

Evaluation of Prostate Cancer Based on MALDI-TOF MS Fingerprinting of Nanoparticle-Treated Serum Proteins/peptides.

A Novel Algorithm for Multi-class Cancer Diagnosis on MALDI-TOF Mass Spectra

Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification

[Fragments Woven into a Whole: A New Approach to the Diagnosis of Cancer through Mass Spectrometry and Machine-Learning]

Multidimensional Interactive Cascading Nanochips for Detection of Multiple Liver Diseases via Precise Metabolite Profiling

DNA-framework-based multidimensional molecular classifiers for cancer diagnosis

Efficient Serum Lipids Profiling by TiO2-dopamin-assisted MALDI-TOF MS for Breast Cancer Detection

An integrated platform for decoding hydrophilic peptide fingerprints of hepatocellular carcinoma using artificial intelligence and two-dimensional nanosheets

Data mining techniques for cancer detection using serum proteomic profiling.

Advancing Serum Peptidomic Profiling by Data-Independent Acquisition for Clear-Cell Renal Cell Carcinoma Detection and Biomarker Discovery.

An end-to-end deep learning method for mass spectrometry data analysis to reveal disease-specific metabolic profiles

A vision for better health: mass spectrometry imaging for clinical diagnostics.

Electro-Optical Multiclassification Platform for Minimizing Occasional Inaccuracy in Point-of-Care Biomarker Detection